SB Sleep Breathe Well Sleep & Pulmonary Education
Home › Lung Health › Lung Cancer Screening / Lung Cancer Treatment

Lung Cancer Treatment

Treatment for lung cancer depends on the cancer type (non-small cell vs. small cell), stage, molecular profile, and the patient's overall health and lung function. Major advances in immunotherapy and targeted therapy have transformed outcomes over the past decade.

Lung cancer types

  • Non-small cell lung cancer (NSCLC): Accounts for approximately 80–85% of lung cancers. Subtypes include adenocarcinoma (most common), squamous cell carcinoma, and large cell carcinoma.[1]
  • Small cell lung cancer (SCLC): Approximately 10–15% of cases. Tends to grow and spread rapidly. Strongly associated with smoking. Staged as limited or extensive.[1]
  • Molecular profiling: Tumors are now routinely tested for specific gene mutations and biomarkers (EGFR, ALK, ROS1, BRAF, KRAS G12C, NTRK, MET, RET, PD-L1 expression) that guide targeted therapy and immunotherapy decisions.

Staging basics

  • NSCLC is staged I–IV using the TNM system (tumor size, lymph node involvement, metastasis).[1]
  • Early stage (I–II): Tumor confined to the lung or nearby lymph nodes — potentially curable with surgery.
  • Locally advanced (III): Spread to regional lymph nodes — may be treated with combined chemotherapy, radiation, and sometimes surgery or immunotherapy.
  • Advanced/metastatic (IV): Cancer has spread to distant organs — treatment focuses on extending life and managing symptoms.
  • Staging evaluation includes CT chest/abdomen, PET scan, brain MRI, and sometimes mediastinoscopy or endobronchial ultrasound (EBUS) for lymph node sampling.
Surgery

Surgical treatment

Surgery offers the best chance of cure for early-stage NSCLC and is the preferred treatment for stage I and II disease in patients with adequate lung function.[1]

Types of surgery
  • Lobectomy: Removal of the entire lobe containing the tumor — the standard of care for most operable lung cancers
  • Sublobar resection: Removal of a smaller portion (segmentectomy or wedge resection). Increasingly used for small peripheral tumors (<2 cm) based on recent trial data showing comparable outcomes
  • Pneumonectomy: Removal of an entire lung — reserved for central tumors that cannot be treated with lobectomy
  • VATS and robotic surgery: Minimally invasive approaches (video-assisted thoracoscopic surgery) reduce pain, hospital stay, and recovery time compared to traditional open thoracotomy
Pre-operative evaluation
  • Pulmonary function testing: Spirometry and DLCO to assess whether the patient can tolerate lung resection. Predicted postoperative FEV1 and DLCO are calculated.
  • Cardiopulmonary exercise testing (CPET): May be needed if pulmonary function is borderline to determine surgical risk. Learn more →
  • Quantitative perfusion scanning: Helps estimate how much functional lung will remain after surgery.
  • Cardiac evaluation: To assess perioperative cardiac risk.
Systemic Therapies

Chemotherapy, immunotherapy, and targeted therapy

Systemic (whole-body) treatments are used alone or in combination with surgery and radiation depending on cancer stage and molecular profile.

Chemotherapy
  • Platinum-based doublet chemotherapy (cisplatin or carboplatin combined with a second agent) remains a backbone of lung cancer treatment[1]
  • Used as adjuvant therapy (after surgery) for stage II–III to reduce recurrence
  • Used as neoadjuvant therapy (before surgery) — increasingly combined with immunotherapy to shrink tumors before resection
  • Remains the primary treatment backbone for small cell lung cancer, often combined with immunotherapy
  • Common side effects include fatigue, nausea, cytopenias (low blood counts), neuropathy, and kidney toxicity
Immunotherapy
  • Immune checkpoint inhibitors have revolutionized lung cancer treatment. They work by releasing the brakes on the immune system, allowing T cells to attack cancer cells.[2]
  • PD-1/PD-L1 inhibitors: Pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi)
  • CTLA-4 inhibitors: Ipilimumab (Yervoy) — sometimes combined with PD-1 inhibitors
  • PD-L1 expression: A biomarker that helps predict immunotherapy response. High PD-L1 (≥50%) is associated with better response to single-agent immunotherapy
  • Neoadjuvant immunotherapy: Nivolumab + chemotherapy before surgery (CheckMate 816) has shown improved outcomes in resectable NSCLC
  • Immune-related side effects: Can affect any organ — pneumonitis (lung inflammation), colitis, hepatitis, thyroiditis, dermatitis, and others. Monitoring and early recognition are critical.

Targeted therapy and novel medications

  • EGFR inhibitors: Osimertinib (Tagrisso) is the standard of care for EGFR-mutant NSCLC. Shown to improve survival in both advanced and early-stage (adjuvant) settings.[2]
  • ALK inhibitors: Alectinib (Alecensa), lorlatinib (Lorbrena), and others for ALK-rearranged NSCLC
  • KRAS G12C inhibitors: Sotorasib (Lumakras) and adagrasib (Krazati) — first-ever targeted agents for the most common KRAS mutation in NSCLC
  • Other targets: ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK — each with FDA-approved targeted therapies
  • Antibody-drug conjugates (ADCs): Trastuzumab deruxtecan (Enhertu) for HER2-mutant NSCLC and other ADCs represent an expanding class of treatments
  • Perioperative targeted therapy: Osimertinib is now used as adjuvant therapy after surgery for EGFR-mutant NSCLC (ADAURA trial), and neoadjuvant targeted therapy trials are ongoing
  • Molecular testing is essential: Comprehensive genomic profiling should be performed on all advanced NSCLC to identify actionable targets. This fundamentally changes treatment selection and outcomes.
Radiation Therapy

Radiation for lung cancer

Radiation therapy uses high-energy beams to kill cancer cells. It plays a role at nearly every stage of lung cancer, either as definitive treatment, adjunctive therapy, or for symptom palliation.[1]

Types of radiation
  • Stereotactic body radiation therapy (SBRT/SABR): Delivers very high, precisely targeted doses over 3–5 sessions. Used for early-stage NSCLC in patients who cannot undergo surgery or decline surgery. Cure rates for stage I NSCLC approach 85–95% local control.
  • Conventional external beam radiation: Delivered over 5–7 weeks. Used for locally advanced lung cancer, typically combined with concurrent chemotherapy (chemoradiation).
  • Consolidation immunotherapy: After chemoradiation for stage III NSCLC, durvalumab (Imfinzi) for up to 12 months has significantly improved survival (PACIFIC trial).[2]
  • Prophylactic cranial irradiation (PCI): Low-dose whole-brain radiation to prevent brain metastases, used in limited-stage SCLC after treatment response.
  • Palliative radiation: Used to relieve symptoms from advanced cancer — bone pain, airway obstruction, brain metastases, or superior vena cava syndrome.
Side effects of thoracic radiation
  • Radiation pneumonitis: Inflammation of the lung occurring 1–6 months after radiation. Symptoms include cough, shortness of breath, and low-grade fever. Treated with corticosteroids. Can progress to radiation fibrosis (permanent scarring).
  • Esophagitis: Inflammation of the esophagus causing pain with swallowing, especially during concurrent chemoradiation.
  • Fatigue: Common during and after treatment.
  • Skin changes: Redness and irritation over the treatment area.
  • Cardiac toxicity: Long-term risk when radiation fields include the heart. Modern techniques aim to minimize cardiac dose.
  • Rib fractures: Uncommon but can occur in the radiation field, especially with SBRT.
Complications

Pulmonary complications of cancer therapies

Cancer treatments — including chemotherapy, immunotherapy, targeted therapy, and radiation — can all cause lung toxicity. Recognizing these complications early is critical because they can mimic cancer progression or infection.[3]

Drug-induced lung toxicity
  • Chemotherapy agents: Bleomycin, busulfan, carmustine, methotrexate, gemcitabine, and taxanes can all cause pulmonary toxicity. Bleomycin lung toxicity is dose-dependent and can cause irreversible fibrosis.[3]
  • Immune checkpoint inhibitor pneumonitis: Occurs in 3–5% of patients on PD-1/PD-L1 inhibitors and up to 10% with combination immunotherapy. Presents as new or worsening cough, dyspnea, and ground-glass opacities on CT. Graded by severity — mild cases may allow rechallenge; severe cases require permanent discontinuation and high-dose corticosteroids.
  • Targeted therapy lung toxicity: EGFR inhibitors (osimertinib), mTOR inhibitors (everolimus), CDK4/6 inhibitors, and antibody-drug conjugates can all cause interstitial lung disease. T-DXd (trastuzumab deruxtecan) carries a notable risk of ILD requiring close monitoring.
  • Radiation recall pneumonitis: Lung inflammation in a previously irradiated field triggered by subsequent systemic therapy, particularly immunotherapy or certain chemotherapies.
Other pulmonary complications
  • Radiation fibrosis: Permanent scarring that develops 6–24 months after thoracic radiation. Usually stable but can cause chronic cough, dyspnea, and restrictive physiology.
  • Infection: Cancer patients are immunocompromised from chemotherapy and disease. Opportunistic infections (Pneumocystis, Aspergillus, CMV) must be considered alongside typical bacteria.
  • Venous thromboembolism: Cancer is a major risk factor for pulmonary embolism. New shortness of breath in a cancer patient warrants PE evaluation.
  • Pleural effusions: Malignant effusions are common in advanced lung cancer. May require thoracentesis (drainage) or pleurodesis (procedure to prevent reaccumulation).
  • Airway obstruction: Central tumors can obstruct airways, causing post-obstructive pneumonia, atelectasis, or respiratory distress. Interventional bronchoscopy (stenting, debulking) can provide relief.
  • Post-surgical complications: Air leak, pneumonia, respiratory failure, bronchopleural fistula, and persistent pain after thoracic surgery.

When to seek evaluation

Any new or worsening cough, shortness of breath, chest pain, or unexplained fever during or after cancer treatment should be reported to the oncology team promptly. Early imaging (CT chest) and sometimes bronchoscopy are needed to distinguish drug toxicity from infection or cancer progression.

Related topics

Trusted resources

References

  1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. Version 2026. Available from: nccn.org
  2. Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586-597. doi:10.1200/JCO.21.01497
  3. Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. doi:10.3390/jcm7100356